Analysis of Safety Outcomes in Chronic Hepatitis C Patients using Interferon-free Treatment: A Systematic Review of Case Reports

Author(s): Vinicius Lins Ferreira*, Leticia Paula Leonart, Ana Maria Della Rocca, Roberto Pontarolo.

Journal Name: Current Drug Therapy

Volume 14 , Issue 3 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Second generation direct acting-antivirals are safe and effective treatments for chronic hepatitis C patients.

Objective: We aimed to conduct a systematic review of case reports and case series to evaluate the safety of the drugs, highlighting a compilation of AE not previously reported in other reviews.

Methods: The search was performed in four electronic databases and included only case reports and case series that evaluated interferon-free therapies and provided safety outcomes.

Results: Initially 1,235 records were retrieved, and after screening 30 studies were included in the analysis (23 case reports and 7 case series). A total of 39 patients were included, receiving eight different interferon-free treatments. Nineteen patients discontinued treatment (only 8 of these achieved treatment response). Other 19 patients achieved SVR without discontinuation. Rare adverse events were observed, including breast hypertrophy, retinopathy and drug-induced infection. Some patients were in an advanced stage of the disease, and were therefore unable to withstand treatment due to the appearance of complications.

Conclusion: In this sense, it is important to monitor the use of these drugs that can favor the appearance of serious AE. (PROSPERO registration number CRD42016051680).

Keywords: Interferon-free, hepatitis C, case report, systematic review, case series, treatment.

[1]
World Health Organization (WHO). Hepatitis C Fact Sheet No 164. WHO Web site. 2017. Available From. http: //www.who.int/mediacentre/factsheets/fs164/en/ Accessed on: May 02, 2017.
[2]
Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of interferon-free therapies for chronic hepatitis C: a systematic review of all randomized clinical trials. Clin Drug Investig 2017; 37: 635-46.
[3]
AASLD-IDSA. Recommendations for testing, managing, and treating hepatitis C. Available From http: //www.hcvguidelinesorg 2016 Accesses on: May 02, 2017.
[4]
Ferreira VL, Assis Jarek NA, Tonin FS, Borba HHL, Wiens A, Pontarolo R. Safety of interferon-free therapies for chronic hepatitis C: a network meta-analysis. J Clin Pharm Ther 2016; 41: 478-85.
[5]
European Association for Study of Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-36.
[6]
(WHO) WHO. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection Updated version, April 2016.
[7]
Ferreira VL, Assis Jarek NA, Tonin FS, et al. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis. J Gastroenterol Hepatol 2017; 32: 749-55.
[8]
FakhriRavari A. Malakouti M, Brady R. Interferon-Free treatments for chronic hepatitis C genotype 1 infection. J Clin Transl Hepatol 2016; 4: 97-112.
[9]
Danish SH, Reza Z, Sohail AA. Case reports and their importance in medical literature. JPMA J Pakistan Med Ass 2017; 67: 451-3.
[10]
Nayak BK. The significance of case reports in biomedical publication. Indian J Ophthalmol 2010; 58: 363-4.
[11]
Ferreira VL, Leonart LP, Tonin FS, Borba HHL, Pontarolo R. Sustained virological response in special populations with chronic hepatitis C using interferon-free treatments: a systematic review and meta-analysis of observational cohort studies. Clin Drug Investig 2018; 38: 389-400.
[12]
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009; 6(7)e1000100
[13]
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0: Cochrane 2011.
[14]
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12.
[15]
Bonacci M, Londoño MC, Esforzado N, Forns X, Sotoca JM, Campistol JM. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list. Transpl Int 2015; 28: 1345-9.
[16]
Carrier P, Jaccard A, Jacques J, et al. HCV-associated B-cell non-Hodgkin lymphomas and new direct antiviral agents. Liver Int 2015; 35: 2222-7.
[17]
Chin-Loy K, Galaydh F, Shaikh S. Retinopathy and uveitis associated with sofosbuvir therapy for chronic hepatitis C infection. Cureus 2016; 8e597
[18]
Debes JD, Ricci P. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir. Dig Liver Dis 2015; 47: 1091-2.
[19]
Fujii Y, Uchida Y, Mochida S. Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir. Hepatology 2015; 61: 400-1.
[20]
Gentili M, Magni C, Carnovale C, et al. Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina. Breast J 2016; 22: 708-9.
[21]
Hasin Y, Shteingart S, Dahari H, et al. Hepatitis C virus cures after direct acting antiviral-related drug-induced liver injury: Case report. World J Hepatol 2016; 8: 858-62.
[22]
Helmers RA, Byrne TJ, Wesselius LJ, Leslie KO. Serious pulmonary toxicity secondary to novel hepatitis C antiviral therapy in a liver transplant recipient. Mayo Clin Proc 2015; 90: 1294-7.
[23]
Hoogeveen RC, Sonnen MPAM, Sankatsing SUC. Visual hallucinations during hepatitis C treatment with sofosbuvir and simeprevir: a case report Infect Dis Clin Pract 2016; 24: E65-E.
[24]
Izzo I, Zanotti P, Chirico C, et al. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C. Infection 2016; 44: 811-2.
[25]
Kamada T, Furuta K, Tomioka H. Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report. Respir Investig 2016; 54: 207-10.
[26]
Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report. Hepatol Res 2016; 46: 707-12.
[27]
Meissner EG, Nelson A, Marti M, Masur H, Osinusi A, Kottilil S. Sustained virologic response for chronic hepatitis C infection after 27 days of treatment with sofosbuvir and ribavirin. Open Forum Infect Dis 2014; 1: 013.
[28]
Ohta Y, Kanda T, Katsuno T, et al. Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report. BMC Gastroenterol 2016; 16: 66.
[29]
Ou P, Fang Z, Chen J. Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report. Clin Res Hepatol Gastroenterol 2017; 41: e17-8.
[30]
Ramadori G, Bosio P, Moriconi F, Malik IA. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy. Aliment Pharmacol Ther 2018; 18: 257.
[31]
Rossotti R, Travi G, Pazzi A, Baiguera C, Morra E, Puoti M. Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report. J Hepatol 2015; 62: 234-7.
[32]
Safadi R, Noviello S, Boparai N, McPhee F. Case report: successful retreatment of hepatitis C genotype 1b infection with sofosbuvir + simeprevir in a patient with cirrhosis who had prior virologic relapse after treatment with daclatasvir and asunaprevir. Clin Case Rep 2016; 4: 653-6.
[33]
Syal G, Heldenbrand SD, Duarte-Rojo A. Seizures as a potential complication of treatment with simeprevir and sofosbuvir. Am J Ther 2016; 23: e570-1.
[34]
Taibi C, Tempestilli M, D’Avolio A. Efficacy of sofosbuvir and ledipasvir in an HCV+ gastro-resected patient. J Clin Pharm Ther 2017; 42: 621-3.
[35]
Weng Q, Li X, Ren H, et al. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature. Oncotarget 2017; 8: 22299-303.
[36]
Wu SYS, Faire B, Gane E. Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK (R)) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction. Case Rep Intern Med 2017.4895736
[37]
Celen MK, Akdemir I, Tekin R, Bayan K, Ayaz C. Elbasvir/grazoprevir experience - a new glance at HCV treatment: case report. Viral Hepatit Dergisi 2017; 23: 34-6.
[38]
Dyson JK, Hutchinson J, Harrison L, et al. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol 2016; 64: 234-8.
[39]
Fontaine H, Lazarus A, Pol S, et al. Bradyarrhythmias Associated with Sofosbuvir Treatment. N Engl J Med 2015; 373: 1886-8.
[40]
Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond) 2015; 47: 924-9.
[41]
Krastev Z, Jelev D, Antonov K, et al. Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma. World J Gastroenterol 2016; 22: 2630-5.
[42]
Renard S, Borentain P, Salaun E, et al. Severe pulmonary arterial hypertension in patients treated for hepatitis C with sofosbuvir. Chest 2016; 149: e69-73.
[43]
Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015; 149: 1378-80.e1.
[44]
Stine JG, Intagliata N, Shah NL, et al. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Dig Dis Sci 2015; 60: 1031-5.
[45]
Rutherford A, Dienstag JL. Viral Hepatitis. In: Greenberger NJ, Blumberg RS, Burakoff R, Eds. Current Diagnosis & Treatment: Gastroenterology, Hepatology, & Endoscopy. 3rd ed. New York: McGraw-Hill Education 2016.
[46]
D’Ambrosio R, Degasperi E, Colombo M, Aghemo A. Direct-acting antivirals: the endgame for hepatitis C? Curr Opin Virol 2017; 24: 31-7.
[47]
Collins LF, Chan A, Zheng J, et al. Direct-acting antivirals improve access to care and cure for patients with HIV and chronic HCV Infection. Open Forum Infect Dis 2018; 5: ofx264-1-.
[48]
Sofosbuvir (Rx). Available From https: //reference. medscape.com/drug/sovaldi-sofosbuvir-999890#4 Medscape 2018. Accessed on May 18, 2018.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 14
ISSUE: 3
Year: 2019
Page: [210 - 219]
Pages: 10
DOI: 10.2174/1574885514666190130162547
Price: $65

Article Metrics

PDF: 31
HTML: 2

Special-new-year-discount